MoonLake Immunotherapeutics annual total assets
2020
2021
2022
2023
2024
2025
MoonLake Immunotherapeutics Total Assets Growth & History (MLTX)
MoonLake Immunotherapeutics's total assets was $424.4M for fiscal 2025.
View full MoonLake Immunotherapeutics company overviewMoonLake Immunotherapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $424.4M | −$53.5M | −11.19% |
| 2024 | 2024-12-31 | $477.9M | −$48.6M | −9.23% |
| 2023 | 2023-12-31 | $526.5M | $449.7M | +585.21% |
| 2022 | 2022-12-31 | $76.8M | $67.2M | +693.63% |
| 2021 | 2021-12-31 | $9.7M | −$107.0M | −91.70% |
| 2020 | 2020-12-31 | $116.6M | — | — |
MoonLake Immunotherapeutics quarterly total assets
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $573.9M | $113.9M | +24.75% |
| Q1 2026 | 2026-03-31 | $400.4M | −$110.9M | −21.69% |
| Q4 2025 | 2025-12-31 | $424.4M | −$53.5M | −11.19% |
| Q3 2025 | 2025-09-30 | $414.3M | −$103.9M | −20.05% |
| Q2 2025 | 2025-06-30 | $460.1M | −$84.8M | −15.56% |
| Q1 2025 | 2025-03-31 | $511.3M | −$52.9M | −9.37% |
| Q4 2024 | 2024-12-31 | $477.9M | −$48.6M | −9.23% |
| Q3 2024 | 2024-09-30 | $518.2M | $18.0M | +3.60% |
| Q2 2024 | 2024-06-30 | $544.9M | $38.3M | +7.55% |
| Q1 2024 | 2024-03-31 | $564.1M | $497.3M | +744.53% |
| Q4 2023 | 2023-12-31 | $526.5M | $449.7M | +585.21% |
| Q3 2023 | 2023-09-30 | $500.2M | $411.6M | +464.63% |
| Q2 2023 | 2023-06-30 | $506.6M | $408.2M | +414.68% |
| Q1 2023 | 2023-03-31 | $66.8M | −$164.4M | −71.11% |
| Q4 2022 | 2022-12-31 | $76.8M | $67.2M | +693.63% |
| Q3 2022 | 2022-09-30 | $88.6M | −$27.7M | −23.79% |
| Q2 2022 | 2022-06-30 | $98.4M | −$17.9M | −15.41% |
| Q1 2022 | 2022-03-31 | $231.2M | $114.7M | +98.48% |
| Q4 2021 | 2021-12-31 | $9.7M | −$107.0M | −91.70% |
| Q3 2021 | 2021-09-30 | $116.2M | — | — |
| Q2 2021 | 2021-06-30 | $116.4M | — | — |
| Q1 2021 | 2021-03-31 | $116.5M | — | — |
| Q4 2020 | 2020-12-31 | $116.6M | — | — |
MoonLake Immunotherapeutics total assets trends
Over the last five fiscal years, MoonLake Immunotherapeutics's total assets increased from $116.6M to $424.4M, a change of $307.8M. The latest reported quarter, Q2 2026, shows $573.9M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MoonLake Immunotherapeutics source filings ↗